Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Calidi Biotherapeutics ( (CLDI) ).
On July 24, 2025, Calidi Biotherapeutics announced the elimination of the President, Medical and Scientific Affairs position, held by Dr. Boris Minev, as part of its organizational restructuring and cost optimization efforts. Dr. Guy Travis Clifton will assume Dr. Minev’s responsibilities. On July 25, 2025, the company announced a 1-for-12 reverse stock split of its common stock, effective August 5, 2025, aimed at optimizing market dynamics and broadening investor appeal.
The most recent analyst rating on (CLDI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on developing targeted therapies capable of delivering genetic medicines to disease sites. The company’s Redtail platform specializes in creating viral vectors for systemic delivery, targeting oncology and potentially other indications. Their lead candidate is in IND-enabling studies for non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs.
Average Trading Volume: 14,410,311
Technical Sentiment Signal: Sell
Current Market Cap: $26.65M
See more insights into CLDI stock on TipRanks’ Stock Analysis page.